Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin

Experimental and Therapeutic Medicine

Volumn 1, Issue 6, 2010, Pages 1013-1017

  Wong, Angela M ^a   Zhang, Yanjung ^a   Kesler, Kelly ^a   Deng, Max ^a   Burhenn, Lucas ^a   Wang, David ^a   Moro, Aune ^a   Li, Zhaoping ^a   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammation; Nuclear factor b; Prostate cancer

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ORIDONIN; PLANT EXTRACT; RABDOSIA RUBESCENS EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHINESE MEDICINE; CONTROLLED STUDY; DRUG DOSE COMPARISON; GENE ACTIVATION; GENOMICS; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROSTATE CANCER; RABDOSIA; RABDOSIA RUBESCENS; TREATMENT DURATION; TUMOR XENOGRAFT;

EID: 78049316336     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.145     Document Type: Article

References (24)

1. National Policy on Traditional Medicine and Regulation of Herbal Medicines: Report of a WHO Global Survery. WHO Press, Geneva, 2005.
2. Hong MY, Seeram NP, Zhang Y and Heber D: Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food 11: 657-666, 2008.
3. Hong MY, Seeram NP, Zhang Y and Heber D: Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 19: 448-458, 2008.
4. Li Z, Seeram NP, Lee R, Thames G, Minutti C, Wang HJ and Heber D: Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. J Altern Complement Med 11: 1031-1038, 2005.
5. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM and Go VL: Cholesterol-lowering effects of a proprietary Chinese redyeast-rice dietary supplement. Am J Clin Nutr 69: 231-236, 1999.
6. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, Thompson PD, Rader DJ and Becker DJ: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 105: 198-204, 2010.
7. Seeram NP, Adams LS, Hardy ML and Heber D: Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem 52: 2512-2517, 2004.
8. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG and Heber D: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphe- nols as found in pomegranate juice. J Nutr Biochem 16: 360-367, 2005.
9. Henning SM, Niu Y, Liu Y, Lee NH, Hara Y, Thames GD, Minutti RR, Carpenter CL, Wang H and Heber D: Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16: 610-616, 2005.
10. Adams LS, Seeram NP, Hardy ML, Carpenter C and Heber D: Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines. Evid Based Complement Alternat Med 3: 117-124, 2006.
11. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
12. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diter- penoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005.
13. Sartippour MR, Seeram NP, Heber D, Hardy M, Norris A, Lu Q, Zhang L, Lu M, Rao JY and Brooks MN: Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol 26: 121-127, 2005.
14. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP and Taguchi H: Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 4: 578-586, 2005.
15. Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via pi3K/ Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 28: 1819-1826, 2007.
16. Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC and Zhang RQ: The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol 103: 176-180, 2006.
17. Wang HJ, Li D, Yang FY, Tashiro S, Onodera S and Ikejima T: Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. J Asian Nat Prod Res 10: 787-798, 2008.
18. Zhang CL, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res 6: 127-138, 2004.
19. Chen S, Gao J, Halicka HD, Huang X, Traganos F and Darzynkiewicz Z: The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol 26: 579-588, 2005.
20. Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S and Ikejima T: NF-kappa B facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys 489: 25-33, 2009.
21. Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S and Ikejima T: Cytochrome C release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci 96: 155-163, 2004.
22. Liu YQ, You S, Tashiro S, Onodera S and Ikejima T: Activation of phosphoinositide 3-kinase, protein kinase C, and extracel- lular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci 98: 361-371, 2005.
23. Wagner H and Ulrich-Merzenich G: Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 16: 97-110, 2009.
24. Ulrich-Merzenich G, Panek D, Zeitler H, Wagner H and Vetter H: New perspectives for synergy research with 'omic' technologies. Phytomedicine 16: 495-508, 2009.